Browse by Poster Presenter

Schedule at a Glance

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Browse by Poster Presenter

Type here to filter the list

Z
Zachariah, Ralph

Department of Medical Oncology and Hematology, Kantonsspital Winterthur
(P 436) SAKK 57/24 FEASIBILITY OF TOTAL NEOADJUVANT TREATMENT WITH HYPERTHERMIA IN PATIENTS WITH HIGH-RISK EXTREMITY AND TRUNK SOFT TISSUE SARCOMA. A MULTICENTER, SINGLE ARM, OPEN LABEL, PHASE II TRIAL
Ralph Zachariah
Favorite
Zadeh, Gelareh

Mayo Clinic
(P 465) JAK/STAT PATHWAY CO-OPERATES WITH CIC-FUSIONS TODRIVE CIC-REARRANGED SARCOMAS
Gelareh Zadeh
Favorite
Zaffaroni, Nadia

Fondazione IRCCS Istituto Nazionale dei Tumori
(P 32) EFFECTIVENESS OF LURBINECTEDIN PLUS IRINOTECAN IN PRECLINICAL MODEL OF DESMOPLASTIC SMALL ROUND CELL TUMOR
Nadia Zaffaroni
Favorite
(P 446) GDF-15 AS A PROGNOSTIC FACTOR IN PATIENTS WITH EPITHELIOID HEMANGIOENDOTHELIOMA
Nadia Zaffaroni
Favorite
Zahler, Stacey

Cleveland Clinic
(P 284) THE IMPACT OF SARCOMA SBRT ON THE IMMUNE SYSTEM: EARLY RESULTS FROM A PROSPECTIVE TRIAL
Stacey Zahler
Favorite
Zaidi, Shane

The Royal Marsden Hospital
(P 414) PATTERNS OF RELAPSE OF BORDERLINE AND MALIGNANT PHYLLODES TUMOUR- RESULTS FROM SARCOMA REFERENCE CENTRE (SRC)
Shane Zaidi
Favorite
Zając, Agnieszka

Maria Sklodowska-Curie National Research Institute of Oncology
(P 139) IMMUNOGENOMIC PROFILING OF CHONDROSARCOMA REVEALS DISTINCT IMMUNE PHENOTYPES AND PROGNOSTIC MUTATIONS
Agnieszka Zając
Favorite
(P 149) SURGICAL TEXTBOOK OUTCOMES IN PATIENTS DIAGNOSED WITH CHONDROSARCOMA
Agnieszka Zając
Favorite
Zambelli, Luca

Fondazione IRCCS Istituto Nazionale dei Tumori di Milano
(P 446) GDF-15 AS A PROGNOSTIC FACTOR IN PATIENTS WITH EPITHELIOID HEMANGIOENDOTHELIOMA
Luca Zambelli
Favorite
(P 447) PAIN ASSESSMENT CRITERIA (PAC) ANTICIPATE RECIST PROGRESSION AND CORRELATE WITH BLOOD LEVELS OF GROWTH DIFFERENTIATION FACTOR 15 (GDF15) IN EPITHELIOID HEMANGIOENDOTHELIOMA (EHE)
Luca Zambelli
Favorite
Zarins, Fiona

Deciphera Pharmaceuticals, LLC
(P 358) EFFECT OF A HIGH-FAT MEAL ON THE PHARMACOKINETICS (PK) OF VIMSELTINIB, AN ORAL INHIBITOR OF THE COLONY-STIMULATING FACTOR 1 RECEPTOR (CSF1R), IN HEALTHY PARTICIPANTS
Fiona Zarins
Favorite
Zarzour, Maria Alejandra

The University of Texas MD Anderson Cancer Center
(P 83) OUTCOMES OF MULTIMODAL PERIOPERATIVE TREATMENT IN OSTEOSARCOMAS OF THE JAW
Maria Alejandra Zarzour
Favorite
(P 451) TREATMENT OUTCOMES OF GEMCITABINE AND DOCETAXEL IN PATIENTS WITH CLEAR CELL SARCOMA (CCS) OR GASTROINTESTINAL NEUROECTODERMAL TUMOR (GNET): A CASE SERIES
Maria Alejandra Zarzour
Favorite
(P 460) OUTCOMES OF LATER-LINES SYSTEMIC THERAPIES IN MALIGNANT PERIPHERAL NERVE SHEATH TUMORS (MPNST)
Maria Alejandra Zarzour
Favorite
Zdzienicki, Marcin

Maria Sklodowska-Curie National Research Institute of Oncology; Warsaw Poland
(P 216) VIRTUAL MULTIDISCIPLINARY MEETINGS IN THE CARE OF SARCOMA PATIENTS
Marcin Zdzienicki
Favorite
Zdzienicki, Marcin

Maria Sklodowska-Curie National Research Institute of Oncology
(P 313) SIGNIFICANCE OF LYMPH NODE PROCEDURES IN SOFT TISSUE SARCOMA PATIENTS
Marcin Zdzienicki
Favorite
Zecca, Ernesto

Fondazione IRCCS Istituto Nazionale dei Tumori di Milano
(P 447) PAIN ASSESSMENT CRITERIA (PAC) ANTICIPATE RECIST PROGRESSION AND CORRELATE WITH BLOOD LEVELS OF GROWTH DIFFERENTIATION FACTOR 15 (GDF15) IN EPITHELIOID HEMANGIOENDOTHELIOMA (EHE)
Ernesto Zecca
Favorite
Zedlitz Johansen, Astrid

National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital—Herlev and Gentofte, Herlev, Denmark
(P 36) MODULATION OF THE SARCOMA MICROENVIRONMENT THROUGH β-ADRENERGIC BLOCKADE
Astrid Zedlitz Johansen
Favorite
Zeissig, Sylke

Bavarian Cancer Registry, Regional Center Würzburg, Bavarian Health and Food Safety Authority
(P 204) ANALYSIS OF QUALITY INDICATORS OF SOFT TISSUE SARCOMA TREATMENT WITH CANCER REGISTRY DATA IN GERMANY 2015-2021
Sylke Zeissig
Favorite
Zemp, Franz

Arnie Charbonneau Cancer Institute and McCaig Institute for Bone and Joint Health
(P 238) INVESTIGATING HOW MACROPHAGES INFILTRATE THE TUMOUR MICROENVIRONMENT AND INFLUENCE THE EFFICACY OF CAR T THERAPY IN A MURINE MODEL OF STS
Franz Zemp
Favorite
(P 378) HIGH DOSE RADIATION THERAPY PROMOTES IMMUNE SUPPRESSIVE MACROPHAGE PHENOTYPES, WHEREAS LOW DOSE RADIATION THERAPY PROMOTES IMMUNOGENIC MACROPHAGE PHENOTYPES IN A MURINE MODEL OF SOFT TISSUE SARCOMA
Franz Zemp
Favorite
Zer, Alona

Rambam Health Care Campus
(P 346) SURROGATE ENDPOINTS FOR OVERALL SURVIVAL IN ADVANCED SOFT TISSUE SARCOMA TRIALS: A SYSTEMATIC REVIEW AND META-ANALYSIS
Alona Zer
Favorite
Zeringo, Nicholas

Deciphera Pharmaceuticals, LLC
(P 422) EFFICACY WITH VIMSELTINIB IN PATIENTS (PTS) WITH TENOSYNOVIAL GIANT CELL TUMOR (TGCT) AND PRIOR COLONY-STIMULATING FACTOR 1 (CSF1) INHIBITOR THERAPY: A PHASE 2 CASE SERIES
Nicholas Zeringo
Favorite
Zervoudakis, Guston

Moffitt Cancer Center
(P 114) DENOSUMAB THERAPY AND MIRELS ADJUSTED ODDS OF PATHOLOGIC FRACTURE OR PROPHYLACTIC STABILIZATION IN APPENDICULAR SKELETAL METASTASES
Guston Zervoudakis
Favorite
Zhang, Chengyue

Deciphera Pharmaceuticals, LLC
(P 358) EFFECT OF A HIGH-FAT MEAL ON THE PHARMACOKINETICS (PK) OF VIMSELTINIB, AN ORAL INHIBITOR OF THE COLONY-STIMULATING FACTOR 1 RECEPTOR (CSF1R), IN HEALTHY PARTICIPANTS
Chengyue Zhang
Favorite
(P 376) EFFECT OF ITRACONAZOLE (ITZ) AND RABEPRAZOLE (RBP) ON THE PHARMACOKINETICS (PK) OF VIMSELTINIB, AN ORAL INHIBITOR OF THE COLONY-STIMULATING FACTOR 1 RECEPTOR, IN HEALTHY PARTICIPANTS
Chengyue Zhang
Favorite
Zhang, Ellen

Stanford Health Care
(P 122) INTERVAL-COMPRESSED CHEMOTHERAPY FOR TREATMENT OF EWING SARCOMA IN ADULTS: A SINGLE INSTITUTION STUDY
Ellen Zhang
Favorite
Zhang, Hua

Clinical Epidemiology Research Center, Peking University Third Hospital
(P 305) COMPARISON OF GOAL-DIRECTED VERSUS EMPIRICAL TRANSFUSION MANAGEMENT IN PATIENTS WITH SEVERE HEMORRHAGE DURING RETROPERITONEAL TUMOR SURGERY
Hua Zhang
Favorite
(P 469) THE IMPACT OF PREOPERATIVE ANEMIA ON POSTOPERATIVE COMPLICATIONS AND SHORT-TERM PROGNOSIS IN RETROPERITONEAL TUMOR SURGERY PATIENTS.
Hua Zhang
Favorite
Zhang, Lingxin

Mount Sinai
(P 15) EZHIP: A NOVEL EPIGENETIC DRIVER OF OSTEOSARCOMA PATHOGENESIS
Lingxin Zhang
Favorite
Zhang, Xiaojing

Liaoning Cancer Hospital & Institute
(P 407) PIMICOTINIB IN TENOSYNOVIAL GIANT CELL TUMOR (TGCT): LONG-TERM EFFICACY, SAFETY, AND PATIENT-REPORTED OUTCOMES FROM THE PHASE 3 MANEUVER STUDY
Xiaojing Zhang
Favorite
Zhang, Xinhua

Sun Yat-sen University
(P 193) CLINICAL ANALYSIS OF RIPRETINIB DOSE ESCALATION IN ADVANCED GISTS AFTER STANDARD DOSE PROGRESSION
Xinhua Zhang
Favorite
Zhao, Binsheng

Memorial Sloan Kettering Cancer Center
(P 273) RADIOMIC PREDICTORS OF SPONTANEOUS PNEUMOTHORAX DURING TYROSINE KINASE INHIBITOR THERAPY FOR LUNG METASTASES
Binsheng Zhao
Favorite
Zhao, Weisong

Department of Orthopaedics, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
(P 07) A LIVING MULTI-OMICS BIOBANK OF PATIENT-DERIVED XENOGRAFT MODELS FOR SARCOMA
Weisong Zhao
Favorite
Zhe, Wang

MGH
(P 392) CLASSIFICATION AND DIFFERENTIATIONOF MYXOID LIPOSARCOMA AND MYXOMA WITH MACHINE LEARNING
Wang Zhe
Favorite
(P 392) DIFFERENTIATION OF MYXOMA AND MYXOID LIPOSARCOMA BASED ON RADIOMICS PHENOTYPES
Wang Zhe
Favorite
Zhou, Lisa

City of Hope National Medical Center
(P 309) RETROPERITONEAL LIPOMAS: MULTICENTER CLINICAL EXPERIENCE WITH AN EXTREMELY RARE DISEASE ENTITY
Lisa Zhou
Favorite
Zhou, Maggie

Stanford University
(P 297) ANALYSIS OF CTDNA KINETICS IN PATIENTS WITH METASTATIC LEIOMYOSARCOMA UNDERGOING LOCOREGIONAL PROCEDURAL INTERVENTION
Maggie Zhou
Favorite
Zhou, Shengfan

Springworks Therapeutics, Inc.
(P 357) DEVELOPMENT OF AN ALGORITHM TO IDENTIFY PATIENTS (PT) WITH DESMOID TUMORS (DT) IN A UNITED STATES (US) CLAIMS DATASET
Shengfan Zhou
Favorite
(P 368) ASSESSMENT OF PAIN DIAGNOSIS AND PAIN MEDICATION USE IN ADULTS TREATED WITH NIROGACESTAT: A UNITED STATES REAL-WORLD ANALYSIS
Shengfan Zhou
Favorite
Zhou, Yong

West China Hospital, Sichuan University
(P 407) PIMICOTINIB IN TENOSYNOVIAL GIANT CELL TUMOR (TGCT): LONG-TERM EFFICACY, SAFETY, AND PATIENT-REPORTED OUTCOMES FROM THE PHASE 3 MANEUVER STUDY
Yong Zhou
Favorite
Zhu, Hong

University of Virginia School of Medicine, Department of Public Health Sciences, Charlottesville, VA, USA
(P 404) OUTCOMES OF NEOADJUVANT THERAPY IN ANGIOSARCOMA PATIENTS: A KAPLAN-MEIER-RECONSTRUCTED INDIVIDUAL PATIENT-LEVEL META-ANALYSIS
Hong Zhu
Favorite
Zhu, Hongwen

New York Medical College
(P 76) CD47 BLOCKADE SYNERGIZES WITH CHEMOTHERAPY IN ENHANCING MACROPHAGE PHAGOCYTOSIS OF EWING SARCOMA CELLS
Hongwen Zhu
Favorite
Zick, Aviad

Oncology Department, Sharett Institute for Oncology, Hadassah Medical Center & Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel
(P 06) RAPID, POINT-OF-CARE DNA METHYLATION & MOLECULAR LANDSCAPE BASED SARCOMA CLASSIFICATION
Aviad Zick
Favorite
Ziegler, Jordan

PrecisionNextGen Oncology and Research Center
(P 230) CIRCULATING TUMOR DNA AS AN EARLY INDICATOR OF RESPONSE, PROGRESSION, AND RECURRENCE OF SARCOMAS
Jordan Ziegler
Favorite
(P 433) PHASE I DOSE ESCALATION TRIAL OF STX-001, AN LNP SELF-REPLICATING MRNA EXPRESSING IL-12, IN PATIENTS WITH REFRACTORY TUMORS INCLUDING SARCOMAS
Jordan Ziegler
Favorite
(P 440) CASE REPORT: COMPLETE CLINICAL AND MOLECULAR RESPONSE TO INTRATUMORAL STX-001, AN LNP-SELF REPLICATING MRNA EXPRESSING IL-12 IN A PATIENT WITH REFRACTORY ANGIOSARCOMA
Jordan Ziegler
Favorite
(P 471) COMBINATION CHEMOTHERAPY WITH GEMCITABINE AND PACLITAXEL: A HIGHLY EFFICACIOUS AND BETTER TOLERATED OPTION FOR ANGIOSARCOMA
Jordan Ziegler
Favorite
Zijlstra, IJsbrand

Department of Radiology, Amsterdam University Medical Center
(P 294) RISK FACTORS FOR RECURRENCE AND COMPLICATIONS OF CT-GUIDED RADIOFREQUENCY ABLATION FOR THE TREATMENT OF OSTEOID OSTEOMA: A MULTI-INSTITUTIONAL ANALYSIS.
IJsbrand Zijlstra
Favorite
Zilli, Thomas

Department of Radiation Oncology, Institute of Southern Switzerland
(P 436) SAKK 57/24 FEASIBILITY OF TOTAL NEOADJUVANT TREATMENT WITH HYPERTHERMIA IN PATIENTS WITH HIGH-RISK EXTREMITY AND TRUNK SOFT TISSUE SARCOMA. A MULTICENTER, SINGLE ARM, OPEN LABEL, PHASE II TRIAL
Thomas Zilli
Favorite
Zimel, Melissa

University of California San Francisco
(P 93) INTERCALARY COMPRESSIVE OSSEOINTEGRATION OF DIAPHYSEAL TUMORS: A MULTI-INSTITUTIONAL CASE SERIES
Melissa Zimel
Favorite
Zoghbi, Marianne

MD Anderson Cancer Center
(P 184) MTAP IN GASTROINTESTINAL STROMAL TUMOR (GIST): RATE OF MTAP LOSS AND CONCORDANCE BETWEEN GENOMIC SEQUENCING AND IMMUNOHISTOCHEMISTRY
Marianne Zoghbi
Favorite
Zokaasadi, Mohammad

Duke University
(P 259) PRECLINICAL MODELING OF CHEMOTHERAPY RELEASE IDENTIFIES MITOCHONDRIAL ADAPTATIONS IN DOXORUBICIN TREATED OSTEOSARCOMA
Mohammad Zokaasadi
Favorite
Zuco, Valentina

Fondazione IRCCS Istituto Nazionale dei Tumori
(P 32) EFFECTIVENESS OF LURBINECTEDIN PLUS IRINOTECAN IN PRECLINICAL MODEL OF DESMOPLASTIC SMALL ROUND CELL TUMOR
Valentina Zuco
Favorite
(P 446) GDF-15 AS A PROGNOSTIC FACTOR IN PATIENTS WITH EPITHELIOID HEMANGIOENDOTHELIOMA
Valentina Zuco
Favorite
(P 447) PAIN ASSESSMENT CRITERIA (PAC) ANTICIPATE RECIST PROGRESSION AND CORRELATE WITH BLOOD LEVELS OF GROWTH DIFFERENTIATION FACTOR 15 (GDF15) IN EPITHELIOID HEMANGIOENDOTHELIOMA (EHE)
Valentina Zuco
Favorite
(P 452) EFFECTIVENESS OF ERIBULIN FOR MYXOID PLEOMORPHIC LIPOSARCOMA: INSIGHTS FROM A PATIENT-DERIVED MODEL AND CLINICAL TRANSLATION IN A PATIENT WITH ADVANCED DISEASE
Valentina Zuco
Favorite
Zugazagoitia, Jon

HOSPITAL UNIVERSITRIO 12 OCTUBRE
(P 445) TEADES PH1/2 STUDY WITH ODM-212: PRELIMINARY RESULTS IN EHE PATIENTS
Jon Zugazagoitia
Favorite
Zumarraga, Juan

Foundation Metrofraternidad
(P 151) SHOULD WE USE ADJUVANT CHEMOTHERAPY IN PATIENTS WITH LOCALIZED DEDIFFERENTIATED CHONDROSARCOMA (DDCS) OF THE PELVIS? AN ANALYSIS BY THE PELVIC DDCS STUDY GROUP
Juan Zumarraga
Favorite